(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) rose by a staggering 34.62% in 21 sessions from $1.56 at 2022-10-10, to $2.10 at 10:11 EST on Monday, following the last session’s downward trend. NASDAQ is rising 1.28% to $10,475.25, following the last session’s upward trend.

Inovio Pharmaceuticals’s last close was $2.11, 72.84% below its 52-week high of $7.77.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing, commercializing, and marketing DNA medicines. These drugs are used to protect and treat people against diseases such as cancer, human papillomavirus, and other infectious diseases. The DNA medicines platform utilizes precisely-designed SynCon to identify and optimize DNA sequences of target antigens. CELLECTRA smart device technology facilitates the delivery of DNA plasmids. It plans clinical trials of DNA medicines to treat HPV-related precancers such as cervical, vulvar and anal dysplasia. ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, (DARPA), Defense Advanced Research Projects Agency, Defense Advanced Research Projects Agency, Department of Defense (DoD), HIV Vaccines Trial Network, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals, Thero Fisher Scientific, Thermo Fisher Military Institute of Research, The Wistar Institute of Research, University of Research, Walter Reed Army Institute of Research, University of Research, University of Research, University of Research, University of Research, University of Research, Thero Fisher Scientific, Thermo Fisher Research, Thermo Fisher to support thero Fisher Scientific, Thermo Fisher Research, Thermo Fisher Research, Thermo Fisher, and Thermo Fischer Thermo and Thero and Thermo and Thermo and Thermo and The Wistar Institute. To support the investigational DNA vaccine, INO-4800 for COVID-19, Richter-Helm BioLogics GmbH & Co. KG has been entered into an agreement. The partnership also includes International Vaccine Institute (Seoul National University Hospital) and Regeneron Pharmaceuticals. Plymouth Meeting is the headquarters of this company, which was established in 1979.

Earnings per Share

Inovio Pharmaceuticals’ trailing 12 months profit per share was $-1.073.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -70.1%.

Annual Top and Bottom Value

At 10:12 EST Inovio Pharmaceuticals’ stock was valued at $2.10, which is way lower than its 52 week high of $7.77 but much higher than its low 52-week of $1.38.

Revenue Growth

Year-on-year quarterly revenue growth declined by 46.4%, now sitting on 1.6M for the twelve trailing months.


Inovio Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.59%, a positive 1.36%, and a positive 4.99%.

Inovio Pharmaceuticals’s highest amplitude of average volatility was 1.06% (last week), 4.73% (last month), and 4.99% (last quarter).

More news about Inovio Pharmaceuticals (INO).


Please enter your comment!
Please enter your name here